๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 8 Beijing 7 Guangzhou 5 Tianjin 2 Jinan 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai8 Beijing7 Guangzhou5 Tianjin2 Jinan2
All 22 locations
Target enrolment
to

Trials with a site in Beijing

7 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
NCT07208149Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
42
Beijing
2026-01-29
Recruiting
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
NCT06732323Triple-Negative Breast Cancer (TNBC)
Qilu Pharmaceutical Co., Ltd.
Phase 3
504
Beijing
2025-09-04
By invitation
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer๏ผˆUPGRADE-TNBC๏ผ‰
NCT06910072Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
32
Beijing
2025-07-21
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT05490472Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
102
Beijing, Changchun, Jinan
2022-12-20
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

4 of the 7 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 7 studies
PhaseStudiesRecruitingShare
Phase 33242.9%
Phase 1/22228.6%
Phase 11014.3%
Phase 2/31014.3%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Adcentrx Therapeutics10
Akeso11
Biotheus Inc.10
Cancer Institute and Hospital, Chinese Academy of Medical Sciences10
Jacobio Pharmaceuticals Co., Ltd.11
Qilu Pharmaceutical Co., Ltd.11
Shenzhen Majory Biotechnology Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.